Literature DB >> 16685312

Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists.

Jeff S Healey1, Sean Wharton, Saif Al-Kaabi, Menaka Pai, Amir Ravandi, Girish Nair, Carlos A Morillo, Stuart J Connolly.   

Abstract

BACKGROUND: Hypertension is common in patients with atrial fibrillation (AF) and is an important cause of stroke.
OBJECTIVES: To determine how effectively hypertension is managed among specialist-treated outpatients with AF.
METHODS: Investigators reviewed the charts of patients with a diagnosis of AF cared for by medical specialists to determine the change in blood pressure, patterns of antihypertensive drug use and the role of the specialist in the management of hypertension.
RESULTS: Of 209 patients with AF, 118 had a history of hypertension or an office blood pressure greater than 140/90 mmHg. Blood pressure was measured at 73% of all visits. Hypertension was identified as an important problem in 57% of patients and antihypertensive therapy was either initiated or suggested in 77%. One year after the initial specialist visit, systolic blood pressure was significantly lower (140+/-20 mmHg at one year versus 148+/-23 mmHg initially; P=0.015); however, there was no change in diastolic blood pressure (80+/-12 mmHg at one year versus 81+/-16 mmHg initially; P=0.602) and only 50% of patients had a blood pressure less than 140/90 mmHg. In contrast, the percentage of patients receiving warfarin increased from 46% to 78% (P=0.0001).
CONCLUSIONS: In patients treated by specialists for AF, systolic blood pressure is significantly reduced during follow-up; however, 50% of patients continue to have suboptimal blood pressure control. In many patients, hypertension is not identified as an important comorbid illness and antihypertensive therapy is neither recommended nor initiated by the specialist. Greater specialist involvement in the identification and treatment of hypertension in patients with AF could lead to an important, additional reduction in stroke.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16685312      PMCID: PMC2560549          DOI: 10.1016/s0828-282x(06)70265-3

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  25 in total

1.  Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists.

Authors:  Philip Jong; Yanyan Gong; Peter P Liu; Peter C Austin; Douglas S Lee; Jack V Tu
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

2.  Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies.

Authors:  R G Hart; L A Pearce; V T Miller; D C Anderson; J F Rothrock; G W Albers; E Nasco
Journal:  Cerebrovasc Dis       Date:  2000 Jan-Feb       Impact factor: 2.762

3.  Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Oucome dello Scompenso Cardiaco in relazione all'Utilizzo delle Risore.

Authors:  P Bellotti; L P Badano; N Acquarone; R Griffo; G Lo Pinto; A P Maggioni; C Mattiauda; G Menardo; P Mombelloni
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

4.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

5.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.

Authors:  Gregory W Albers; Hans-Christoph Diener; Lars Frison; Margaretha Grind; Mark Nevinson; Stephen Partridge; Jonathan L Halperin; Jay Horrow; S Bertil Olsson; Palle Petersen; Alec Vahanian
Journal:  JAMA       Date:  2005-02-09       Impact factor: 56.272

6.  Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial.

Authors:  N Chapman; R Huxley; C Anderson; M G Bousser; J Chalmers; S Colman; S Davis; G Donnan; S MacMahon; B Neal; C Warlow; M Woodward
Journal:  Stroke       Date:  2003-12-11       Impact factor: 7.914

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

9.  Blood pressure and cardiovascular disease in the Asia Pacific region.

Authors:  C M M Lawes; A Rodgers; D A Bennett; V Parag; I Suh; H Ueshima; S MacMahon
Journal:  J Hypertens       Date:  2003-04       Impact factor: 4.844

10.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

Authors:  Alan S Go; Elaine M Hylek; Yuchiao Chang; Kathleen A Phillips; Lori E Henault; Angela M Capra; Nancy G Jensvold; Joe V Selby; Daniel E Singer
Journal:  JAMA       Date:  2003-11-26       Impact factor: 56.272

View more
  2 in total

1.  Academic cardiac electrophysiologists' perspectives on sleep apnea care.

Authors:  Michael Dong; Linda Liu; Kenneth C Bilchick; Nishaki K Mehta; Yoon-Sik Cho; Ryan J Koene; Selcuk Adabag; Adrian Baranchuk; Neal A Chatterjee; T Jared Bunch; Hirad Yarmohammadi; Younghoon Kwon
Journal:  Sleep Breath       Date:  2022-06-01       Impact factor: 2.816

2.  Hypertension in Middle Eastern Arab and South Asian Patients with Atrial Fibrillation: From a 20-Year Hospital Registry in Qatar (1990-2010).

Authors:  Amar M Salam; Imtiaz Salim; Rasha Kaddoura; Rajvir Singh; Nidal Asaad; Awad Al-Qahtani; Jassim Al Suwaidi; Hajar A AlBinali
Journal:  Heart Views       Date:  2022-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.